XT
SLN

XTX Topco’s Silence Therapeutics SLN Stock Holding History

XTX Topco’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$559K Buy
106,002
+94,284
+805% +$519K 0.01% 1938
2025
Q4 		$71.2K Buy
+11,718
New +$75K ﹤0.01% 2739

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

XTX Topco's SLN Position: Q1 2026 in Review

XTX Topco increased its Silence Therapeutics (SLN) stake by 805% in Q1 2026, buying an estimated $519K and bringing the position to 106,002 shares worth $559K. The position accounts for 0.01% of the portfolio, ranked #1938.

XTX Topco first reported a position in SLN in Q4 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • XTX Topco held 106,002 shares of Silence Therapeutics worth $559K as of Q1 2026.
  • XTX Topco bought 94,284 Silence Therapeutics shares in Q1 2026, an estimated $519K.
  • Silence Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #1938 holding.
  • XTX Topco first reported a position in Silence Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.